This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Every major pharma company is now involved in CGT development which has resulted in the approval of 28 therapies by the FDA thereby making CGT no longer a niche category of therapies. Allogeneic therapies begin with healthy donor samples to develop the eventual therapeutic product which can be administered to multiple patients.
Signant Health has partnered with the software company o connect its platforms for the management of clinicalsupplychain inventory, labels, and content.
Supplychain uncertainty is a challenge every clinicalsupplychain manager wrestles with – stemming from increasing product demand and quality, the growing complexity of clinical trial designs and a lack of visibility in the supplychain.
Analyzing the benefits and challenges of implementing direct-to-patient services in the clinicalsupplychain to help meet patient requirements, improve supplychain efficiency and accelerate speed to market.
The benefits of developing a patient-centric clinicalsupplychain.
However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinicalsupplychains.
Find out solutions to mitigate the impact from clinicalsupplychain risk and discover how to improve dynamic drug supply forecasting strategies. Enrolling study subjects, setting up patient randomization and managing drug supply are critical to the success of a clinical trial. .
7am PDT.
As the clinical trials industry adapts to the rising demand, it must also tackle important challenges concerning the way advanced medicines like cell and gene therapies are handled. Cell and gene therapies are not your typical clinicalsupplychain. That was really a key part of the design.
BioNTech plans to manufacture additional therapeutic and vaccine drug candidates at the plant, such as other mRNA vaccines, antibody and cell and gene therapy candidates to support the development of its diversified cancer and infectious disease product pipeline.
This innovative platform aims to revolutionize the industry by seamlessly connecting providers, distributors and suppliers, providing unprecedented visibility into supply and demand information. Developed in collaboration with Palantir Technologies Inc.,
company (NASDAQ: AMZN), announced that it is working with Pfizer to create innovative, cloud-based solutions with the potential to improve how new medicines are developed, manufactured, and distributed for testing in clinical trials. (AWS), an Amazon.com, Inc.
Therefore, the available patient pool of a majority Black population in Africa represents an invaluable opportunity to develop medical products for patients with unmet clinical needs. Therefore, they are open to clinical trials, because of the lack of costs that they have to put towards it. being African American, 3.4%
With many clinical trial participants from Ukraine leaving the country after the outbreak of the war, clinical research organisations (CROs) played a crucial role in ensuring trial continuity. Oximio’s team have worked around the clock to ensure continuity in the clinicalsupplychain in Ukraine.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content